ALNY vs. SNY: Alnylam Pharmaceuticals vs. Sanofi Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Alnylam Pharmaceuticals (ALNY) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Alnylam Pharmaceuticals (ALNY) at 138.07% clears its industry range for ROE, a sharper capital-efficiency signal than Sanofi (SNY) at 5.72%, which is closer to a typical peer reading.

Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Sanofi (SNY) at 5.49% is closer to the peer norm — faster top-line expansion for ALNY.

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Sanofi (SNY) at 0.27 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Alnylam Pharmaceuticals (ALNY) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Sanofi (SNY) at 23.40 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Alnylam Pharmaceuticals (ALNY) at 4.17 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Alnylam Pharmaceuticals (ALNY) at 5.79 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics